Roche Alzheimer’s Drug Fails, Joining Long List of Trial Flops | Top News

ZURICH (Reuters) – An experimental Alzheimer’s drug from Roche

and AC Immune

failed to slow cognitive and functional decline in a trial, the Swiss companies said on Wednesday, in a fresh setback to efforts to fight the fatal dementia-causing disease.

AC Immune boss Andrea Pfeifer described the results of the trial of semorinemab as “surprising and disappointing”.

The drug targets “tau” proteins believed to play a role in Alzheimer’s and offers an alternative to treatments aiming to fight amyloid beta peptides in the brain.

The outcome of the Phase 2 trial – in patients with an early stage of Alzheimer’s – means the failure rate for drugs aiming to fight the brain-wasting illness, which afflicts tens of millions of people worldwide, remains at nearly 100%.

“We believe the full data analysis of this first-of-its-kind study will yield information about this promising target that will advance our understanding and inform future

Read More